What Берголак Treats: Main Uses and Benefits

The medication is commonly used to manage conditions and symptoms that arise from abnormally high levels of the hormone prolactin (hyperprolactinemia). This therapeutic approach is considered relevant in contexts involving heightened systemic burden.

Therapeutic Scope and Key Benefits

Берголак is generally applied across conditions presenting with systemic or localized discomfort caused by excess prolactin. This includes managing pathological hyperprolactinemia, supporting the medical treatment of prolactin-secreting pituitary tumors (prolactinomas), and addressing hyperprolactinemia-related reproductive symptoms such as irregular or absent menstrual cycles, infertility, and sexual dysfunction.

The therapeutic approach generally seeks to provide support that helps ease the overall symptom burden. One patient-focused understanding of this drug is:

“The therapy is applied when symptoms create noticeable physiological strain and interference with daily comfort.”

This medication is also relevant for easing discomfort related to established physiological lactation when suppression is medically appropriate. By addressing symptoms that interfere with daily functioning, it may assist with managing acute or disruptive episodes and supports general well-being during symptomatic phases and is relevant for easing symptoms that interfere with daily comfort.

---

Quick Fact: Relief for Inappropriate Secretion This medication is often applied to manage symptoms of inappropriate milk production (galactorrhea) and is commonly used to help with managing symptoms related to the suppression of established lactation when medically necessary.

Regulatory References

1. NIH MedlinePlus overview of Cabergoline

Eligibility Map: Who Can and Cannot Use Берголак (Cabergoline) — Official Regulatory Information

Eligibility Scope	Category	Official Regulatory Statement
Allowed Population	Adults with hyperprolactinemic disorders.
Use Not Recommended	Breastfeeding mothers and for suppression of physiological lactation.

---

Populations for whom use is Contraindicated	Condition	Regulatory Classification
Hypersensitivity to Cabergoline or Ergot Derivatives	Contraindicated
Uncontrolled Hypertension	Contraindicated
Cardiac Valvulopathy or Fibrotic Disorders (Pulmonary, Retroperitoneal)	Contraindicated

---

Age and Condition-Specific Rules

• Age-Related Eligibility: Safety and efficacy have not been established in the pediatric population. Experience in older adults is very limited but without special noted risk.
• Conditional Use: Caution is required for patients with severe hepatic insufficiency, a history of serious psychotic mental disorders, or severe cardiovascular disease.
• Pregnancy Status: Pregnancy must be excluded before treatment initiation.

---

Connection to the overall eligibility profile Official regulatory documents strictly define non-eligibility through a series of absolute contraindications tied to the drug’s ergot class and potential for fibrotic/valvular risks. Eligibility is further constrained by age-group limitations and specific cautions for patients with severe hepatic or mental health histories.

Interactions with other medicines and products

Official regulatory documents classify interactions with Cabergoline based primarily on pharmacodynamic effects and documented restrictions, rather than extensive metabolic pathways.

Interaction Type	Official Regulatory Statement	Restriction
Dopamine Antagonists	May antagonize the prolactin-lowering effect [DailyMed].	Co-administration is generally not recommended (e.g., Metoclopramide).
Antihypertensive Agents	Potential to potentiate hypotensive effects, particularly orthostatic hypotension [DailyMed].	Use with caution, especially at the start of therapy.
Other Ergot Alkaloids	Potential for additive effects due to shared chemical class [FDA Label].	Co-administration is not recommended.

The drug is predominantly metabolized via hydrolysis, meaning that interactions mediated by Cytochrome P450 enzymes are not expected to be clinically significant. However, certain non-enzyme interactions are noted: some regulatory bodies restrict co-administration with Macrolide antibiotics due to the potential for increased systemic exposure of Cabergoline [EMA SmPC]. Furthermore, the use of alcohol may enhance Central Nervous System side effects, such as somnolence [MedlinePlus]. Interaction risk is also documented to be heightened in patients with severe hepatic impairment, resulting in substantially altered drug exposure [FDA Label].

How Берголак Works

The mechanism of action for Берголак is defined by its specific, direct modulation of the neuroendocrine system.

Targeted D2 Receptor Agonism on Pituitary Cells

The drug acts as a high-affinity agonist (stimulant) of the D2 dopamine receptors located directly on the lactotroph cells of the anterior pituitary gland. This targeted interaction mimics the inhibitory signal normally sent by the hypothalamus via the tuberoinfundibular pathway. This initial step establishes a long-lasting, suppressive bond with its cellular target.

Signal Transduction Shutdown and Endocrine Suppression

Binding to the D2 receptor initiates an inhibitory G-protein ( Gi) signaling cascade that effectively shuts down the cell's internal machinery. This process inhibits adenylyl cyclase, sharply reducing the secondary messenger cAMP and limiting the intracellular calcium required for hormone release. The resulting physiological consequence is a sustained suppression of prolactin synthesis and secretion from the pituitary gland.

Sustained Mechanistic Engagement and Constraint

The drug's mechanism is characterized by its exceptionally prolonged functional presence at the receptor site, allowing for prolonged endocrine pathway modulation. This action is subject to mechanistic limitations, specifically being vulnerable to functional counteraction by substances classified as D2 receptor antagonists, which physically block the drug from initiating its inhibitory signal.

How to Use Берголак (Cabergoline)

Берголак is administered solely via the oral route as a tablet. The administration protocol is typically structured around a gradual, titration-based schedule intended to achieve and maintain normalized prolactin levels.

Official Administration Protocol

Usage Principle	Guidance
Starting Dose	For hyperprolactinemic disorders, the typical starting dose is 0.25 mg administered twice weekly.
Dose Adjustments	Dosing increases, if needed, must occur at intervals of no less than four weeks. The standard increment is 0.25 mg twice weekly.
Maximum Dose	The maximum recommended dose for hyperprolactinemia is generally 1 mg twice weekly (2 mg total per week), though higher doses are noted in clinical documentation.
Timing & Food	Tablets may be taken with or without food. Taking the tablet with meals may be advised to improve patient tolerability.

Procedural and Population Rules

Administration involves a slow, measured approach where dose progression is tied directly to the body's response. Dosage adjustments must be guided by periodic measurement of serum prolactin levels, often monitored at monthly intervals until the target level is sustained. The tablets are scored to facilitate accurate administration of the required 0.25 mg doses.

For chronic use, therapy may be considered for discontinuation after serum prolactin levels have remained normal for approximately six months, followed by subsequent monitoring. The use of Cabergoline is not established in the pediatric population (under 16 or 18 years), as safety and efficacy have not been demonstrated in this age group.

Research evidence / Overview of studies for Берголак

---

Evidence for Use in Non-Tumoral Hyperprolactinemia

This area of research was studied for conditions characterized by abnormally high levels of the hormone prolactin that are not caused by a pituitary tumor. Short-term clinical trials and long-term observational studies were applied in research exploring how outcomes related to functional imbalance change over time in the studied populations. Specifically, research examined key outcomes such as the normalization of serum prolactin levels and changes related to reproductive health, including markers of menstrual cycles and the change in inappropriate milk secretion (galactorrhea). The populations in these studies were predominantly adult women with this condition.

Studies report how symptoms evolved, describing patterns where prolactin levels were measured at normal levels during the study period. Findings also described patterns of change in reproductive function markers observed in groups using the medicine. There is a general absence of recent clinical trials that use a placebo as a comparator to assess long-term clinical symptom changes.

---

Evidence for Use in Prolactin-Secreting Pituitary Tumors (Prolactinomas)

The research for this indication was evaluated in conditions related to the presence of prolactin-secreting tumors. Studies explored the effects on tumor volume reduction, measured using MRI scans, and the normalization of prolactin levels. The populations included adult men and women with small (micro-) and large (macro-) prolactinomas.

Findings describe patterns including frequent tumor volume reduction in the studied populations. Evidence suggests that local symptoms, such as visual function, were among the outcomes observed in some studies with patients who had large tumors. Long-term effects on tumor control, particularly after five years of treatment, are not fully established.

---

Long-Term Studies and Durability of Response

The studies in this area were primarily observational cohort studies, designed to track patients after the medicine was stopped. The research monitored the rate and timing of the recurrence of hyperprolactinemia. Studies report that the frequency of recurrence of high prolactin levels following discontinuation was tracked in the studied populations, with findings indicating that recurrence was measured as occurring within the first year in many of the studies.

---

What is Still Uncertain in the Research Landscape

Comparative evidence is lacking to definitively establish long-term performance against older or alternative treatments for sustained tumor size reduction. Furthermore, there is limited information for long-term outcomes regarding the durability of response following drug withdrawal, with highly variable recurrence rates described in the literature. Data for certain specific populations, such as children and older adults, is more limited.

Key Studies & References

1. Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis

Common questions about Берголак (FAQ)

---

Q: Чем Берголак отличается от Достинекса (в целом)?

According to official regulatory sources, the active ingredient in both Берголак and Dostinex is cabergoline. Consequently, the active ingredients have the same mechanism of action and treat the same conditions, as confirmed by regulatory agencies.

Q: Как быстро начинает действовать Берголак?

Regulatory information indicates that cabergoline begins its action to lower prolactin levels quickly, and this suppressive effect is prolonged due to the drug’s long half-life. Official guidance suggests that prolactin levels are typically checked around four weeks after starting treatment to properly assess the therapeutic response.

Q: Через какое время можно заметить эффект от Берголака?

The therapeutic effect of this medication is primarily measured by periodic blood tests of serum prolactin levels. Regulatory guidance indicates that prolactin levels are often monitored on a monthly basis to assess how well the medicine is working and to guide potential dose adjustments.

Q: Берголак как влияет на менструальный цикл?

Official product information states that cabergoline is indicated for treating dysfunctions associated with hyperprolactinemia. This includes reproductive health issues like amenorrhea (absence of menstruation) and oligomenorrhea (infrequent menstruation), and is used as part of a regimen to address the underlying hormonal imbalance.

Q: Почему после приема Берголака может болеть голова?

Headache is listed in regulatory documents as a very common side effect. As a dopamine agonist, the drug acts on the central nervous system, and this action is associated with the occurrence of headaches in many patients.

Q: Что будет, если резко прекратить прием Берголака?

The official documentation emphasizes that stopping the medication may result in the return of high prolactin levels (recurrence of hyperprolactinemia). This is why discontinuation should always be determined by a healthcare specialist.

Q: Можно ли пить кофе или алкоголь во время лечения Берголаком?

Regulatory information advises that consuming alcohol may enhance side effects related to the central nervous system, such as drowsiness. There are no specific restrictions set in official documents regarding the consumption of coffee or caffeine.

Q: Как Берголак влияет на планирование беременности?

The official label specifies that pregnancy must be ruled out before starting treatment with this medication. Official guidance suggests consulting a specialist regarding discontinuing the medication, often recommending cessation approximately one month prior to attempting conception.

Q: Может ли Берголак влиять на вес тела (набор или снижение)?

Changes in body weight, including both weight gain and weight loss, have been noted in regulatory documents as possible, though less common, adverse reactions.

Q: Почему Берголак вызывает тошноту у некоторых людей?

Nausea is reported as a very common adverse reaction in official safety profiles. This common adverse reaction is thought to be related to the drug's mechanism of action, which involves stimulating dopamine receptors in the body.

Q: Почему Берголак нельзя принимать беременным?

The drug is generally not recommended during pregnancy, as data is limited. Use is restricted to situations where the potential benefit is judged to outweigh the potential risks. Official guidance confirms that pregnancy must be excluded before treatment initiation.

Q: Есть ли синдром отмены после прекращения приема Берголака?

While regulatory sources do not describe a classic physical or mental withdrawal syndrome, monitoring is advised after stopping therapy. The main risk tracked after discontinuation is the recurrence of high prolactin levels (hyperprolactinemia).

Q: Берголак используют только для прекращения лактации?

No, this is incorrect. The main indications for cabergoline are the treatment of hyperprolactinemic disorders, such as those causing reproductive dysfunctions (amenorrhea, galactorrhea) and managing prolactin-secreting pituitary tumors (prolactinomas).

Q: Почему Берголак принимают так редко (раз в неделю)?

The drug is prescribed infrequently, typically twice a week, because it is a long-acting dopamine receptor agonist. Official pharmacokinetic data confirms it has a prolonged half-life, which allows for sustained effectiveness with less frequent dosing.

Q: Влияет ли Берголак на настроение или эмоции?

Yes, regulatory documents list adverse reactions related to mood and emotions, including nervousness and depression. Furthermore, certain impulse control disorders, such as pathological gambling and hypersexuality, have been reported in the safety profile.

Q: Что делать, если пропущена таблетка Берголака?

Official instructions are available for managing missed doses. If a dose is forgotten, patients are generally advised to take it as soon as they remember, unless it is nearly time for the next dose. Patients are strictly advised not to take a double dose to compensate.

Q: Почему пролактин повышается, и как помогает Берголак?

The drug is indicated for hyperprolactinemic disorders, which can be caused by reasons like idiopathic hyperprolactinemia or prolactin-secreting pituitary adenomas. It helps by suppressing the synthesis and secretion of prolactin from the pituitary gland.

Q: Безопасно ли принимать Берголак длительное время?

Long-term use requires mandatory safety monitoring, as regulatory sources report an increased risk of specific conditions, particularly cardiac valvulopathy (heart valve damage) and fibrotic disorders. A regular cardiovascular assessment, including monitoring the heart using an echocardiogram, is typically required for patients receiving long-term therapy.

Q: Что делать, если при приеме Берголака болит живот?

Abdominal pain is listed as a common adverse reaction. Official information notes that taking the tablet with food may help improve overall gastrointestinal tolerability. If pain becomes severe or persistent, professional medical evaluation is necessary.

Q: Берголак влияет на способность водить машину?

Yes, official warnings exist regarding the risk of side effects like drowsiness (somnolence) and sudden episodes of falling asleep. Due to the potential for side effects like drowsiness and sudden sleep episodes, patients are cautioned to consider this risk when operating vehicles or machinery.

Q: Почему Берголак может вызвать сухость во рту?

Dry mouth is listed in some regulatory documents as a possible adverse reaction. This is a general side effect associated with the drug’s pharmacological action on the nervous system.

Q: Почему Берголак используют для лечения аденомы гипофиза?

The medication is indicated for treating prolactin-secreting pituitary tumors (prolactinomas), which are a type of pituitary adenoma. The drug is effective because it reduces the excessive production of prolactin and may also help decrease the size of the tumor.

Q: Можно ли принимать Берголак, если я уже принимаю антидепрессанты?

Caution is advised when taking any psychoactive medicines concurrently with cabergoline. Regulatory documents note that the drug is contraindicated in patients with a history of serious psychotic disorders. Official guidance indicates that concomitant use must be supervised and evaluated.

Q: Нужно ли менять диету при приеме Берголака?

Based on official drug information, there are no specific dietary changes required while taking this medication unless otherwise instructed by the prescribing physician.

Official Storage and Disposal Requirements

The storage of Cabergoline (Берголак) tablets is strictly defined by regulatory guidelines to ensure stability. The medication must be kept at a controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The product must be stored in its original container with the desiccant intact and be protected from both light and moisture. It is required to keep the medicine out of the sight and reach of children and to keep it from freezing.

For disposal, unused or expired medication must be handled according to local regulations. Authorities strongly recommend utilizing a drug take-back program. Regulatory documents advise against flushing the tablets down a toilet or pouring them down a drain.